Is Abbott Laboratories (ABT) Pricing Reflect Its Medical Device And Diagnostics Momentum?

Simply Wall St.01-21

If you are wondering whether Abbott Laboratories at around US$121 a share is offering fair value or a potential mispricing, you are in the right place. The stock is modestly positive over 1 year with ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605611484?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","is_english":true,"pubTime":"2026-01-21 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605611484","market":"us","top_or_hot":-1,"title":"Is Abbott Laboratories (ABT) Pricing Reflect Its Medical Device And Diagnostics Momentum?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Abbott Laboratories at around US$121 a share is offering fair value or a potential mispricing, you are in the right place. The stock is modestly positive over 1 year with ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-pricing-reflect-its-medical-devic\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Abbott Laboratories (ABT) Pricing Reflect Its Medical Device And Diagnostics Momentum?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Abbott Laboratories (ABT) Pricing Reflect Its Medical Device And Diagnostics Momentum?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-21 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-pricing-reflect-its-medical-devic><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Abbott Laboratories at around US$121 a share is offering fair value or a potential mispricing, you are in the right place. The stock is modestly positive over 1 year with ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-pricing-reflect-its-medical-devic\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0266013472.USD","symbol_name":"AXA WF - Framlington Longevity Economy A Cap USD","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-pricing-reflect-its-medical-devic","article_id":"2605611484","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-pricing-reflect-its-medical-devic","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2605611484","pubTimestamp":1769005930,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Abbott Laboratories at around US$121 a share is offering fair value or a potential mispricing, you are in the right place.\nThe stock is modestly positive over 1 year with a 5.7% return, but has seen shorter term pullbacks with a 2.5% decline over 7 days and a 3.4% decline over 30 days, while the 3 and 5 year figures sit at 14.2% and 15.7% respectively.\nRecent headlines around Abbott Laboratories have focused on its position in medical devices and diagnostics, as...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4585":"ETF&股票定投概念","LU0882574055.USD":"富达全球健康医疗A ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","BK4566":"资本集团","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0122379950.USD":"贝莱德世界健康科学A2","LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","BK4082":"医疗保健设备","LU0058720904.USD":"联博国际健康护理基金A","BK4504":"桥水持仓","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4592":"伊斯兰概念","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4568":"美国抗疫概念","BK4588":"碎股","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","ABT.AU":"Abundant Produce","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","SG9999002232.USD":"Allianz Global High Payout USD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1989763690.USD":"东方汇理世代食品基金A2 Acc","SGXZ41872573.SGD":"ALLIANZ SGD INCOME PLUS \"AM\" (SGD) INC","BK4581":"高盛持仓","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","ABT":"雅培","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD"},"translate_title":"雅培实验室(ABT)的定价是否反映了其医疗设备和诊断业务的发展势头？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT.AU":1.5,"ABT":1.5,"DCF":1},"content_text":"If you are wondering whether Abbott Laboratories at around US$121 a share is offering fair value or a potential mispricing, you are in the right place. The stock is modestly positive over 1 year with a 5.7% return, but has seen shorter term pullbacks with a 2.5% decline over 7 days and a 3.4% decline over 30 days, while the 3 and 5 year figures sit at 14.2% and 15.7% respectively. Recent headlines around Abbott Laboratories have focused on its position in medical devices and diagnostics, as well as ongoing product updates and regulatory approvals that keep the brand in the healthcare spotlight. This background helps frame why the market may be reassessing both the company's risk profile and its long term growth potential. Our valuation checks give Abbott Laboratories a 3 out of 6 valuation score. This suggests some signals of undervaluation. We will walk through different methods that support or challenge that number, before closing with an approach that many investors find gives an even clearer read on value.  Abbott Laboratories delivered 5.7% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry. AdvertisementApproach 1: Abbott Laboratories Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model looks at the cash Abbott Laboratories is expected to generate in the future and discounts those cash flows back to today to estimate what the business might be worth per share. Based on the latest model, Abbott’s last twelve months Free Cash Flow is about $6.8b. Analysts have provided specific forecasts for the next few years, and Simply Wall St then extends those out using its own assumptions. For example, the projections include Free Cash Flow figures such as $8.4b in 2026 and $8.4b again in 2029, with further years extrapolated through 2035 using the 2 Stage Free Cash Flow to Equity approach. When all those projected cash flows are discounted back to today, the model arrives at an estimated intrinsic value of about $73.28 per share. Compared with the current share price of around $121, this implies the stock is about 65.3% above the model’s estimate, so on this DCF view Abbott screens as overvalued. Result: OVERVALUED Our Discounted Cash Flow (DCF) analysis suggests Abbott Laboratories may be overvalued by 65.3%. Discover 874 undervalued stocks or create your own screener to find better value opportunities. ABT Discounted Cash Flow as at Jan 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Abbott Laboratories. Approach 2: Abbott Laboratories Price vs Earnings For a profitable business like Abbott Laboratories, the P/E ratio is a useful way to see how much you are paying for each dollar of earnings. Investors usually accept a higher P/E if they expect stronger growth or see the earnings as relatively stable, while a lower P/E can reflect lower growth expectations or higher perceived risk. Abbott currently trades on a P/E of about 15.1x. That is below the Medical Equipment industry average P/E of roughly 31.4x and also below the peer group average of about 47.4x. On the surface, that points to the market assigning a lower earnings multiple than many of Abbott’s peers. Simply Wall St’s Fair Ratio for Abbott is 26.9x. This is a proprietary estimate of what a reasonable P/E might be for the company given factors such as its earnings growth profile, industry, profit margins, market value and specific risks. Because it adjusts for these company level characteristics, the Fair Ratio aims to be more tailored than a simple comparison with industry or peer averages. With the current P/E of 15.1x sitting below the 26.9x Fair Ratio, this framework suggests the shares may be trading below what those fundamentals might justify. Result: UNDERVALUED NYSE:ABT P/E Ratio as at Jan 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1444 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Abbott Laboratories Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple tool that lets you attach a clear story about Abbott Laboratories to your own numbers such as fair value, future revenue, earnings and margins. A Narrative connects three pieces in one place: your view of the business, the financial forecast that view implies, and the fair value that follows from those assumptions. On Simply Wall St, Narratives live in the Community page and are used by millions of investors. You can quickly see different fair value estimates, compare them with the current share price, and decide whether the gap between Fair Value and Price supports a buy, hold or sell decision for you. Because Narratives update automatically when new information arrives, such as earnings releases or major news, your story and its fair value stay aligned with the latest data. For example, one Abbott Laboratories Narrative on the Community page might assume conservative revenue growth and a cautious Fair Value near the lower end of the community range, while another could assume stronger growth and a higher Fair Value near the top of that range. Do you think there's more to the story for Abbott Laboratories? Head over to our Community to see what others are saying! NYSE:ABT 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605611484","isCrawlerRequest":true}